Merck & Co. MRK Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $65.01B+1.3% | $64.17B+6.7% | $60.11B+1.4% | $59.28B+21.7% | ||
| $16.38B+7.8% | $15.19B-5.8% | $16.13B-7.4% | $17.41B+27.8% | ||
| $48.63B-0.7% | $48.98B+11.3% | $43.99B+5.1% | $41.87B+19.4% | ||
| 74.8%-1.5pp | 76.3%+3.1pp | 73.2%+2.5pp | 70.6%-1.4pp | ||
| $15.79B-12.0% | $17.94B-41.2% | $30.53B+125% | $13.55B+10.6% | ||
| $10.73B-0.8% | $10.82B+3.0% | $10.5B+4.6% | $10.04B+4.2% | ||
| $889M+187% | $310M-48.2% | $599M+77.2% | $338M-48.8% | ||
| $21.07B+5.7% | $19.94B— | —— | $16.44B+18.5% | ||
| $2.81B+0.1% | $2.8B— | —— | $1.92B+26.0% | ||
| $18.25B+6.6% | $17.12B— | —— | $14.52B+11.3% | ||
| 28.1%+1.4pp | 26.7%— | —— | 24.5%-2.3pp | ||
| $7.29+8.3% | $6.73— | —— | $5.71+11.1% | ||
| $7.30+8.0% | $6.76— | —— | $5.72+10.6% | ||
| $43.94B-0.7% | $44.23B-24.0% | $58.23B+35.9% | $42.84B+23.0% | ||
| -$152M— | —— | -$465M+70.5% | -$1.58B-217% | ||
| $24.11B+9.4% | $22.04B— | —— | $18.27B+18.2% | ||
| 37.1%+2.7pp | 34.3%— | —— | 30.8%-0.9pp | ||
| $21.07B+5.7% | $19.94B— | —— | $16.44B+18.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Merck & Co.'s revenue?
- Merck & Co. (MRK) generated $65.8B in revenue over the trailing twelve months, up 2.9% year over year.
- Is Merck & Co. profitable?
- Merck & Co. reported $8.9B in net income over the trailing twelve months, a 13.6% net margin.
- What is Merck & Co.'s earnings per share?
- Merck & Co.'s diluted EPS over the trailing twelve months is $3.56.
- Where does Merck & Co.'s income statement data come from?
- Every line is extracted from Merck & Co.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
